Characteristics of 21 transplant recipients
| Recipient age, y (range) . | 36 (13-56) . |
|---|---|
| Donor age, y (range) | 36 (16-58) |
| Sex, n (%) | |
| Male | 11 (52) |
| Female | 10 (48) |
| Disease distribution | |
| CML | 17 (81) |
| AML/MDS | 3 (14) |
| MM | 1 (5) |
| Stem cell source | |
| BM | 15 (71) |
| PBSC | 6 (29) |
| Acute GVHD grade II-IV | 6 (29) |
| History of cGVHD | |
| None | 3 (14) |
| Limited | 13 (62) |
| Extensive | 5 (24)* |
| IST for cGVHD | |
| > 3 years | 6 (29) |
| At study | 1 (5) |
| Follow-up period, years, median (range) | 12 (10-15) |
| Recipient age, y (range) . | 36 (13-56) . |
|---|---|
| Donor age, y (range) | 36 (16-58) |
| Sex, n (%) | |
| Male | 11 (52) |
| Female | 10 (48) |
| Disease distribution | |
| CML | 17 (81) |
| AML/MDS | 3 (14) |
| MM | 1 (5) |
| Stem cell source | |
| BM | 15 (71) |
| PBSC | 6 (29) |
| Acute GVHD grade II-IV | 6 (29) |
| History of cGVHD | |
| None | 3 (14) |
| Limited | 13 (62) |
| Extensive | 5 (24)* |
| IST for cGVHD | |
| > 3 years | 6 (29) |
| At study | 1 (5) |
| Follow-up period, years, median (range) | 12 (10-15) |
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; cGVHD, chronic graft-versus-host disease; CML, chronic myelogenous leukemia; GVHD, graft-versus-host disease; IST, immunosuppressive therapy; MDS, myelodysplastic syndrome; and MM, multiple myeloma.
One recipient with active cGVHD at the time of study.